CLL Practice in Focus: Pharmacist Perspectives on BTK Inhibitor Therapy Across Community and Academic Settings

Meeting Objectives:

• • Characterize the pharmacist’s role, unmet needs, and guideline application in CLL care across community and academic settings.
  • Evaluate patient-specific factors that drive CLL treatment and BTKi selection, AE management, and adherence through case-based discussion.
  • Compare continuous BTKi therapy with fixed-duration regimens, including patient selection and operational considerations.
  • Identify lessons learned from IPAY 2026 and best practices for preparing for IPAY 2027 MFP implementation.